期刊文献+

Chou-Talalay在抗肿瘤联合用药中的研究应用概况 被引量:25

Study and Application of Chou-Talalay Method for Anti-tumor Drug Combination
原文传递
导出
摘要 联合用药已经广泛地运用于多种疾病的治疗过程中,如抗菌、抗病毒、抗肿瘤等治疗领域。然而,目前为止国内外学者关于联合用药后疗效的评价标准仍没有达成一致,尤其是药物协同作用的评价。Chou-Talalay是目前被广泛认可的药物协同作用定量分析方法。本文针对抗肿瘤研究领域,对该法的研究应用概况作一综述,为合理用药的研究提供线索和参考。 Drug combination has been widely used in the therapeutic process of many serious illness, such as anti-bacterial, anti-viral and anti-tumor therapeutic, etc. However, so far the domestic and overseas scholars about evaluation standards of the curative effects have not arrived at any agreement yet, especially the synergistic effect of drug combination. Chou-Talalay method is now generally accepted as synergy quantitative analysis method for drug combination. Aiming at the anti-tumor research field, we comprehensively reviewed the method to lay a good basis for the rational use of drugs.
出处 《中国现代应用药学》 CAS CSCD 2013年第4期449-453,共5页 Chinese Journal of Modern Applied Pharmacy
关键词 Chou-Talalay 抗肿瘤 联合用药 定量分析 Chou-Talalay method anti-tumor drug combination quantitative analysis
作者简介 王士群,男,硕士生Tel:(0759)2388405 E-mail:731560548@qq.com 通信作者:郑学宝,男,博士,教授,博导Tel:(0759)2388405 E—mail:xuebaozheng@163.com
  • 相关文献

参考文献18

  • 1GORDON R R,NELSON P S. Cellular senescence and cancerchemotherapy resistance fJ]. Drug Resist Updat, 2012, 15(1/2):123-131.
  • 2TORTORA G, BIANCO R, DANIELE G,et al. Overcomingresistance to molecularly targeted anticancer therapies: rationaldrug combinations based on EGFR and MAPK inhibition forsolid tumours and haematologic malignancies [J]. Drug ResistUpdat, 2007,10(3): 81-100.
  • 3GRECO W R, BRAVO G,PARSONS J C. The search forsynergy: a critical review from response surface perspective [J].Pharmacol Rev, 1995, 47(2): 331-385.
  • 4CHOU T C,MARTIN N. CompuSyn for drug combinations:PC Software and User's Guide: a computer program forquantitation of synergism and antagonism in drugcombinations, and the determination of IC50 and ED50 andLD50 values [J/OL]. ComboSyn, 2005. http: //www.Combosyn.com/ for videodemonstration.
  • 5CHOU T C. Drug combination studies and their synergyquantification using the Chou-Talalay Method [J]. Cancer Res2010,70(2): 440-446.
  • 6CHOU T C. Theoretical basis,experimental design, anccomputerized simulation of synergism and antagonism in drucombination studies [J]. Pharmacol Rev, 2006,68(3): 621-681.
  • 7CHOU T C. The mass-action law based algorithms foiquantitative econo-green bio-research [J]. Integr Biol(Camb)2011,3(5): 548-559.
  • 8JIANG Y,LI C, MA Y, et al. The inhibition of thepemetrexed-activated MAPK pathway via sorafenib isinvolved in the synergistic mechanism of sorafenib subsequenpotentiation of pemetrexed cytotoxicity in EGFR TKI-resistancell lines [J]. Clin Lab, 2012, 58(5/6): 551-561.
  • 9BENNETT C N,TOMLINSON C C, MICHALOWSKI A Met al. Cross-species genomic and functional analyses identify {combination therapy using a CHK1 inhibitor and iribonucleotide reductase inhibitor to treat triple-negative breascancer [J]. Breast Cancer Res, 2012,14(4): R109.
  • 10LIU S H, CHENG Y C. Old formula, new Rx: The journey o:PHY906 as cancer adjuvant therapy [J]. J Ethnopharmacol2012,140(3):614-623.

同被引文献220

引证文献25

二级引证文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部